Preclinical Immunogenicity of a 6-Valent GBS Glycoconjugate Vaccine from a Repeat-Dose GLP Toxicology Study.

ABSTRACT: Background/Objectives: Group B Streptococcus (GBS) is a significant cause of perinatal infection in neonates and infants. Complications could include neonatal sepsis and meningitis, preterm birth, stillbirth, or death. Though no GBS vaccine is currently licensed, maternal immunization is expected to be a highly effective strategy to address invasive GBS disease-particularly in low- and middle-income countries (LMICs), where the disease burden is the greatest and access to existing interventions is limited. In this study, we present a novel hexavalent GBS vaccine candidate with a unique combination of serotypes (ST)-Ia, Ib, II, III, V, and VII-that could be an efficacious and cost-effective intervention, with the broadest coverage of 99% against circulating serotypes globally. Met

SUBMITTER: Bajracharya A 

PROVIDER: S-EPMC12474038 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature